| Outcome Measures: |
Primary: Number of adverse events, 28 to 35 days | Secondary: Changes in vital signs, 28 to 35 days|Changes in physical examination, 28 to 35 days|Changes in ECG, 28 to 35 days|Changes in clinical laboratory parameters (hematology), 28 to 35 days|Changes in clinical laboratory parameters (biochemistry), 28 to 35 days|Changes in body temperature, 28 to 35 days|Change from baseline in biomarkers (FGF21), 28 to 35 days|Change from baseline in biomarkers (lipid biomarker), 28 to 35 days|Change from baseline in biomarkers (incretins), 28 to 35 days|Assessment of pharmacokinetic parameters in blood (AUC), 28 to 35 days|Assessment of pharmacokinetic parameters in blood (Cmax), 28 to 35 days|Assessment of pharmacokinetic parameters in blood (t1/2), 28 to 35 days|Assessment of pharmacokinetic parameters in urine (Ae0-24), 28 to 35 days|Assessment of pharmacokinetic parameters in urine (fe0-24), 28 to 35 days|Change from baseline in Body weight, 28 to 35 days|Change from baseline in Fasting Blood Glucose, 28 to 35 days|Change from baseline in Postprandial Blood Glucose, 28 to 35 days|Change from baseline in postprandial Insulin, 28 to 35 days|Change from baseline in postprandial C-peptide profiles, 28 to 35 days|Change from baseline in HbA1c, 28 to 35 days
|
